Fig. 2.

Involvement of GSK-3β in the antidepressant-like effect of guanosine in the TST. Timeline of experimental protocols of administrations and behavioral tests (a, b). Effect of treatment with sub-effective doses of guanosine and lithium chloride in the immobility time in the TST (guanosine treatment: F_(1,24) = 6.36, p < 0.05; lithium chloride treatment: F_(1,24) = 1.09, p = 0.30; guanosine treatment × lithium chloride interaction: F_(1,24) = 9.15, p < 0.01) (c). Effects of treatment of mice with lithium chloride and guanosine on the locomotor activity in the OFT (guanosine treatment: F_(1,24) = 2.20, p = 0.15; lithium chloride treatment: F_(1,24) = 1.95, p = 0.17; guanosine × lithium chloride interaction: F_(1,24) = 0.13, p = 0.72) (e). Effect of treatment with sub-effective doses of guanosine and AR-A014418 in the immobility time in the TST (guanosine treatment: F_(1,28) = 5.49, p < 0.05; AR-A014418 treatment: F_(1,28) = 1.22, p = 0.27; guanosine treatment × AR-A014418 interaction: F_(1,28) = 5.68, p < 0.05) (d). Effects of pretreatment of mice with AR-A014418 and guanosine on the locomotor activity in the OFT (guanosine treatment: F_(1,28) = 0.45, p = 0.50; AR-A014418 treatment: F_(1,28) = 0.45, p = 0.41; guanosine × AR-A014418 interaction: F_(1,28) = 1.14, p = 0.29) (f). Values are expressed as mean + S.E.M. of 7–8 mice. *p < 0.05 compared with the vehicle-treated control group